During the past decade, Neurodegenerative Disorders Research conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 3 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Neurodegenerative Disorders Research" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Biogen" with 1 trials sponsored, "Innate Immunotherapeutics" with 1 trials sponsored, "Massachusetts General Hospital" with 1 trials sponsored and "Seelos Therapeutics, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Neurodegenerative Disorders Research" #1 collaborator was "National Center for Complementary and Integrative Health (NCCIH)" with 1 trials as a collaborator, "Syneos Health" with 1 trials as a collaborator and "University of Rochester" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Neurodegenerative Disorders Research" are "Alzheimer's Disease" (5 trials), "Behavioral Variant Frontotemporal Dementia (bvFTD)" (1 trials), "Dementia" (1 trials), "Huntington's Disease" (1 trials) and "Secondary Progressive Multiple Sclerosis" (1 trials). Many other conditions were trialed in "Neurodegenerative Disorders Research" in a lesser frequency.

Most popular intervention types in "Neurodegenerative Disorders Research" are "Drug" (9 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Crenezumab" (2 trials), "Aducanumab (BIIB037)" (1 trials), "Creatine Monohydrate" (1 trials) and "Donepezil" (1 trials). Other intervention names were less common.

The vast majority of trials in "Neurodegenerative Disorders Research" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Neurodegenerative Disorders Research". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Neurodegenerative Disorders Research, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Neurodegenerative Disorders Research, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".